Diabetes, insulin and new therapeutic strategies for Parkinson’s disease: Focus on glucagon-like peptide-1 receptor agonists

•Epidemiological studies show a relationship between Parkinson’s disease and Diabetes.•Recent data support repurposing antidiabetic treatments for Parkinson’s disease.•Insulin and GLP1 agonists are a promising strategy against Parkinson’s disease. Parkinson's disease and diabetes mellitus are t...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in neuroendocrinology 2021-07, Vol.62, p.100914, Article 100914
Main Authors: Labandeira, Carmen M., Fraga-Bau, Arturo, Arias Ron, David, Muñoz, Ana, Alonso-Losada, Gema, Koukoulis, Antonio, Romero-Lopez, Jesus, Rodriguez-Perez, Ana I.
Format: Article
Language:English
Subjects:
Diabetes
Exenatide, antidiabetic
GLP
Glucagon-like peptide
Insulin
Neuroinflammation
Neuroprotection
Parkinson
Repurposing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Epidemiological studies show a relationship between Parkinson’s disease and Diabetes.•Recent data support repurposing antidiabetic treatments for Parkinson’s disease.•Insulin and GLP1 agonists are a promising strategy against Parkinson’s disease. Parkinson's disease and diabetes mellitus are two chronic disorders associated with aging that are becoming increasingly prevalent worldwide. Parkinson is a multifactorial progressive condition with no available disease modifying treatments at the moment. Over the last few years there is growing interest in the relationship between diabetes (and impaired insulin signaling) and neurodegenerative diseases, as well as the possible benefit of antidiabetic treatments as neuroprotectors, even in non-diabetic patients. Insulin regulates essential functions in the brain such as neuronal survival, autophagy of toxic proteins, synaptic plasticity, neurogenesis, oxidative stress and neuroinflammation. We review the existing epidemiological, experimental and clinical evidence that supports the interplay between insulin and neurodegeneration in Parkinson's disease, as well as the role of antidiabetic treatments in this disease.
ISSN:0091-3022
1095-6808
DOI:10.1016/j.yfrne.2021.100914